NicOx : Garufi ... e la Rivoluzione Pharma

[osinod]

eccolo ingrandito la porzione di grafico che ci interessa

una chiusura sopra i 10,9 mensile darebbe un breakout rialzista da paura

 

[osinod]

sul weekly dal 2007 ci potrebbe essere un testa spalla di inversione rialzista

non so' se' sia un mia forzatura ma io lo vedo cosi'

 

[osinod]

anche sulle candele giapponesi con bollinger band si evince che il titolo sia vicino ad una svolta importante


CONCLUSIONE GRAFICA SUL TITOLO:

titolo che sta' tendando di invertire trend sul lungo periodo tale tentativo sara' positivo se' riuscira a chiudere in weekly sopra i 10,9$


negativo se' chiudera' il weekly sotto i 6,8$

 

[viralic]

Grazie per gli interessantissimi post......!!!
........Come si può notare si possono dare utili contributi senza cadere perennemente in offese o in stupide diatribe.

 

[Netzach]

Grazie ... ottimo contributo ...

 

[simis]

SJ Berwin takes lead for French drug company on Pfizer development deal
Author: Sofia Lind

09 Sep 2009 | 10:57

Law firms: SJ Berwin

SJ Berwin has won the lead role on a French-American pharma deal, strengthening its relationship with French drug company NicOx.
The City law firm won the mandate to advise NYSE Euronext Paris-listed NicOx as it bought back rights to develop and market an innovative eye disease drug from US pharma giant Pfizer.
The acquisition comes after two previous agreements between the companies in 2004 and 2006, and includes the rights to a new drug for treating glaucoma, as well as technology that could be used for treating other eye diseases currently without any effective treatment. The diseases affect millions worldwide, causing impaired vision or total blindness.
The deal was arranged under English law, with SJ Berwin winning the mandate based on a longstanding relationship with NicOx. It will see Pfizer providing temporary technical support to help with the transition of any clinical tests, with NicOx agreeing to pay Pfizer two lump sums as well as royalties on future sales.
City-based commercial partner Andrew Shindler took the lead for NicOx, while Pfizer relied on its US-based in-house legal team.
Shindler said: "This is the latest in a series of transactions we have concluded for NicOx with large and medium-sized pharmaceutical companies over the last eight or nine years."

 

[Netzach]

SJ Berwin takes lead for French drug company on Pfizer development deal
Author: Sofia Lind

09 Sep 2009 | 10:57

Law firms: SJ Berwin

SJ Berwin has won the lead role on a French-American pharma deal, strengthening its relationship with French drug company NicOx.
The City law firm won the mandate to advise NYSE Euronext Paris-listed NicOx as it bought back rights to develop and market an innovative eye disease drug from US pharma giant Pfizer.
The acquisition comes after two previous agreements between the companies in 2004 and 2006, and includes the rights to a new drug for treating glaucoma, as well as technology that could be used for treating other eye diseases currently without any effective treatment. The diseases affect millions worldwide, causing impaired vision or total blindness.
The deal was arranged under English law, with SJ Berwin winning the mandate based on a longstanding relationship with NicOx. It will see Pfizer providing temporary technical support to help with the transition of any clinical tests, with NicOx agreeing to pay Pfizer two lump sums as well as royalties on future sales.
City-based commercial partner Andrew Shindler took the lead for NicOx, while Pfizer relied on its US-based in-house legal team.
Shindler said: "This is the latest in a series of transactions we have concluded for NicOx with large and medium-sized pharmaceutical companies over the last eight or nine years."

Vu sur Amcox mais je ne savais pas si je pourrais l'afficher ...

Merci SIMIS ...

 

[simis]

pas de prob Net je l'ai mis sur le forum public ))

comme le dit vinsse : the latest .....not the last i hope

 

[coxy]

l'attesa diventa struggente....

 

[Netzach]

Le monoxyde d'azote détient un rôle-clé dans la résistance aux antibiotiques
LEMONDE.FR | 13.09.09 |

Les antibiotiques sont de moins en moins efficaces contre les agents pathogènes qu'ils sont censés combattre. La faute aux résistances qu'ils acquièrent, en raison notamment de traitements antibiotiques pris à mauvais escient. Une étude menée au Centre médical Langone, aux Etats-Unis et publiée vendredi 11 septembre dans la revue "Science" a permis de franchir une étape importante dans la compréhension du phénomène de résistance.

Le monoxyde d'azote (NO), une molécule composée, comme son nom l'indique, d'un atome d'azote et d'un autre d'oxygène, jouerait un rôle primordial dans la résistance des agents pathogènes aux traitements antibiotiques. "Le monoxyde d'azote, écrivent les chercheurs menés par Evgueny Nudler, synthétisé grâce à la bNOS [la NO-synthase, une enzyme] permet à certaines bactéries d'augmenter leur résistance à une large gamme d'antibiotiques". En d'autres termes, le monoxyde d'azote gène l'action des antibiotiques favorisant la survie des bactéries ciblées.

"PLUS EFFICACES À DES DOSES MOINDRES"

Des expérimentations in vivo et in vitro ont montré que la présence d'antibiotique – en l'occurence de la cefuroxime – engendrait une augmentation de l'activité de l'enzyme bNOS et donc de la production de monoxyde d'azote. Ainsi, estiment les chercheurs dans le compte-rendu de leurs travaux, "les bactéries utilisent l'enzyme bNOS comme une [pièce maîtresse] de leur système de défense contre d'autres micro-organismes. (...) L'inhibition de cette enzyme pourrait accroître l'efficacité des thérapies antibiotiques".

Pour Evgueny Nudler, cette découverte permet "un raccourci" car il ne serait plus utile d'inventer "de nouveaux antibiotiques. A la place, nous pouvons renforcer l'action de ceux que nous connaissons bien, en les rendant plus efficaces à des doses moindres."

Le Monde.fr, avec AFP


I NO-Antibiotici ... altra nuova frontiera da sviluppare ???

Forse, però, al momento, ci mancano i partner che ci credano ...